For More Information Contact:
Astellas US LLC
Astellas Pharma Inc.
Astellas to Acquire AMEVIVE® (alefacept)
Acquisition of psoriasis product deepens Astellas’ Commitment to Dermatology franchise
Deerfield, IL and Cambridge, MA, April 3, 2006 – Astellas Pharma US, Inc. and Biogen Idec Inc.
(NASDAQ: BIIB) today announced that an agreement for Astellas to purchase the worldwide rights to
AMEVIVE® (alefacept) was executed as of March 31, 2006. AMEVIVE is a biologic anti-inflammatory
compound used in the treatment of moderate-to-severe plaque psoriasis.
Under the terms of the agreement, Astellas would acquire the worldwide rights to AMEVIVE in all
indications from Biogen Idec. Biogen Idec would continue to manufacture AMEVIVE and supply product
to Astellas. The parties anticipate closing the transaction as early as mid-April.
“The acquisition of a well-established product such as AMEVIVE strengthens our North American
Dermatology franchise and provides Astellas an opportunity to continue offering physicians this effective
option for the treatment of moderate-to-severe plaque psoriasis,” stated William Fitzsimmons, Pharm.D.,
Senior Vice President, Business Development at Astellas Pharma US, Inc.
AMEVIVE is the first biologic approved by the FDA for the treatment of moderate to severe chronic plaque
psoriasis in adults who are candidates for systemic therapy or phototherapy. AMEVIVE is a prescription
medication that is injected by your doctor (15 mg IM, into the muscle) once a week, for a total of 12 doses.
AMEVIVE was approved by the US FDA in January 2003. The most serious adverse reactions found in
clinical trials were: lymphopenia, malignancies, serious infections requirin